- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steven Pearson Discusses Increased Scrutiny on Drug Pricing
As more attention has been drawn to high-cost drugs, the Institute for Clinical and Economic Review has introduced a focus on drug pricing in its reports, explained Steve Pearson, MD, MSc, FRCP, founder and president of ICER.
As more attention has been drawn to high-cost drugs, the Institute for Clinical and Economic Review has introduced a focus on drug pricing in its reports, explained Steve Pearson, MD, MSc, FRCP, founder and president of ICER.
Transcript (modified)
As more attention has been drawn to high-cost drugs, how have ICER’s drug assessment reports evolved?
What’s interesting is that we’ve been doing these reports in a variety of different formats for about 7 years and the key change, in some ways, was when we started looking more explicitly at budget impact—potential budget impact—as well as long-term cost effectiveness. And we were asked around the time of the hepatitis C drugs, by policy makers and by others, “If these drugs are so expensive that they are a poor value or unaffordable, at what price would they have been sensibly priced for the health system?”
And at that point we decided it would be helpful for our reports to include that element, as well. So I think that, along with a lot of other reasons, the policy field has been doing more work on drug pricing. But I think with that addition to our reports, and the fact that we have independent public committees that we convene to debate the evidence, that we take votes on the evidence—you put that package together and I think it’s something that people have been paying a lot more attention to.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
